Clinical Trial

52-week Open Label Safety-Tolerability Study

Name: 52-week Open Label Safety-Tolerability Study — clinical trial record (NCT07369154)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NOVA3

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

Protocol Amendment History 2 changes

critical Recruitment opened 2026-07-28

notable Trial sites expanded: 0 -> 23 locations 2026-05-16

Trial Details

NCT Number	NCT07369154
Lead Sponsor	LB Pharmaceuticals Inc.
Conditions	Schizophrenia
Enrollment	900 participants
Start Date	2026-04-23
Primary Completion	2028-12 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-27